American Journal of Cardiology
Volume 104, Issue 5 , Pages 634-637 , 1 September 2009

Role of Myeloperoxidase as Predictor of Systemic Inflammatory Response Syndrome in Patients With ST-Segment Elevation Myocardial Infarction After Primary Percutaneous Coronary Intervention

  • Sima Samimi-Fard, MD

      Affiliations

    • Department of Cardiology, University Hospital of Canarias, Tenerife, Spain
    • ,
  • Alberto Dominguez-Rodriguez, MD, PhD

      Affiliations

    • Department of Cardiology, University Hospital of Canarias, Tenerife, Spain
    • Corresponding Author InformationCorresponding author: Tel: (+34) 922-67-9030; fax: (+34) 922-36-2716
    • ,
  • Pedro Abreu-Gonzalez, PhD

      Affiliations

    • Department of Physiology, University of La Laguna, School of Medicine, Tenerife, Spain
    • ,
  • Cristina Enjuanes-Grau, MD

      Affiliations

    • Department of Cardiology, University Hospital of Canarias, Tenerife, Spain
    • ,
  • Gabriela Blanco-Palacios, MD

      Affiliations

    • Department of Cardiology, University Hospital of Canarias, Tenerife, Spain
    • ,
  • Idaira F. Hernandez-Baldomero, MD

      Affiliations

    • Department of Cardiology, University Hospital of Canarias, Tenerife, Spain
    • ,
  • Francisco Bosa-Ojeda, MD, PhD

      Affiliations

    • Department of Cardiology, University Hospital of Canarias, Tenerife, Spain
    • ,
  • Francisco Marrero-Rodríguez, MD, PhD

      Affiliations

    • Department of Cardiology, University Hospital of Canarias, Tenerife, Spain

Received 7 March 2009 ,Revised 21 April 2009 ,Accepted 21 April 2009.

References 

  1. Hochman JS, Sleeper LA, Webb JC, Sanborn TA, White HD, Talley JD, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock (SHOCK Investigators. Should we emergently revascularize occluded coronary arteries for cardiogenic shock). N Engl J Med. 1999;341:625–634
  2. Bone RC. Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med. 1996;24:163–172
  3. Neumann FJ, Ott I, Gawaz M, Richardt G, Holzapfel H, Jochum M, et al. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation. 1995;92:748–755
  4. Kohsaka S, Menon V, Lowe AM, Lange M, Dzavik V, Sleeper LA, et al. Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock. Arch Intern Med. 2005;165:1643–1650
  5. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group (Production of C-reactive protein and risk of coronary events in stable and unstable angina). Lancet. 1997;349:462–466
  6. Hochman JS. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation. 2003;107:2998–3002
  7. Zhang R, Brennan ML, Shen Z, Macpherson JC, Schmitt D, Molenda CE, et al. Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. J Biol Chem. 2002;277:46116–46122
  8. Dominguez-Rodriguez A, Samimi-Fard S, Abreu-Gonzalez P, Garcia-Gonzalez MJ, Kaski JC. Prognostic value of admission myeloperoxidase levels in patients with ST-segment elevation myocardial infarction and cardiogenic shock. Am J Cardiol. 2008;101:1537–1540
  9. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. SCMM/ESICM/ACCP/ATS/SIS (2001 SCMM/ESICM/ACCP/ATS/SIS International Sepsis Definition Conference). Intens Care Med. 2001;530–538
  10. Holmes DR. Cardiogenic shock: a lethal complication of acute myocardial infarction. Rev Cardiovasc Med. 2003;4:131–135
  11. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003;349:1595–1604
  12. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Munzel T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation. 2003;108:1440–1445
  13. Cavusoglu E, Chopra V, Gupta A, Ruwende C, Yanamadala S, Eng C, et al. Usefulness of the white blood cell count as a predictor of angiographic findings in an unselected population referred for coronary angioplasty. Am J Cardiol. 2006;98:1189–1193
  14. Cavusoglu E, Ruwende C, Eng C, Chopra V, Yanamadala S, Clark LT, et al. Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndromes. Am J Cardiol. 2007;99:1364–1368
  15. Garcia-Gonzalez MJ, Dominguez-Rodriguez A, Santacreu Iniesta R, Samimi-Fard S, Ferrer-Hita JJ, Rubio-Iglesias Garcia C, et al. Systemic inflammatory response syndrome: incidence and influence on outcome in acute myocardial infarction treated with primary angioplasty. Med Intensiva. 2007;31:289–293
  16. Saadeddin SM, Habbab MA, Sobki SH, Frens GA. Association of systemic inflammatory state with troponin I elevation after elective uncomplicated percutaneous coronary intervention. Am J Cardiol. 2002;89:981–983
  17. Bodi V, Sanchis J, Nunez J, Mainar L, Minana G, Benet I, et al. Uncontrolled immune response in acute myocardial infarction: unraveling the thread. Am Heart J. 2008;156:1065–1073
  18. Hall RI, Smith MS, Rocker G. The systemic inflammatory response to cardiopulmonary bypass: pathophysiological, therapeutic, and pharmacological considerations. Anesth Analg. 1997;85:766–782
  19. Davies MG, Hagen PO. Systemic inflammatory response syndrome. Br J Surg. 1997;84:920–935
  20. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001;104:365–372
  21. Baldus S, Heitzer T, Eiserich JP, Lau D, Mollnau H, Ortak M, et al. Myeloperoxidase enhances nitric oxide catabolism during acute myocardial ischemia and reperfusion. Free Radic Biol Med. 2004;37:902–911
  22. Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2005;25:1102–1111
  23. Askari AT, Brennan ML, Zhou X, Drinko J, Morehead A, Thomas JD, et al. Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med. 2003;197:615–624
  24. Mizock BA, Falk JL. Lactic acidosis in critical illness. Crit Care Med. 1992;20:80–93
  25. Brugger-Andersen T, Hetland O, Ponitz V, Grundt H, Nilsen DW. The effect of primary percutaneous coronary intervention as compared to tenecteplase on myeloperoxidase, pregnancy-associated plasma protein A, soluble fibrin and D-dimer in acute myocardial infarction. Thromb Res. 2007;119:415–421
  26. Li G, Keenan AC, Young JC, Hall MJ, Pamuklar Z, Ohman EM, et al. Effects of unfractionated heparin and glycoprotein IIb/IIIa antagonists versus bivalirudin on myeloperoxidase release from neutrophils. Arterioscler Thromb Vasc Biol. 2007;27:1850–1856

PII: S0002-9149(09)01017-0

doi: 10.1016/j.amjcard.2009.04.049

American Journal of Cardiology
Volume 104, Issue 5 , Pages 634-637 , 1 September 2009

Article Tools

* Image Usage & Resolution